Universe Pharmaceuticals INC
UPC
$4.20
$0.4010.53%
NASDAQ
| 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 6.44M | 6.44M | 6.92M | 6.92M | 9.23M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 6.44M | 6.44M | 6.92M | 6.92M | 9.23M |
| Cost of Revenue | 4.76M | 4.76M | 4.83M | 4.83M | 6.17M |
| Gross Profit | 1.68M | 1.68M | 2.09M | 2.09M | 3.06M |
| SG&A Expenses | 2.52M | 2.52M | 2.61M | 2.61M | 1.83M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -5.70K | -5.70K | 23.80K | 23.80K | 24.40K |
| Total Operating Expenses | 7.31M | 7.31M | 8.76M | 8.76M | 9.16M |
| Operating Income | -870.10K | -870.10K | -1.84M | -1.84M | 74.60K |
| Income Before Tax | -6.22M | -6.22M | -2.05M | -2.05M | 129.50K |
| Income Tax Expenses | 332.60K | 332.60K | 669.60K | 669.60K | 487.20K |
| Earnings from Continuing Operations | -6.55M | -6.55M | -2.72M | -2.72M | -357.70K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -6.55M | -6.55M | -2.72M | -2.72M | -357.70K |
| EBIT | -870.10K | -870.10K | -1.84M | -1.84M | 74.60K |
| EBITDA | -745.60K | -745.60K | -1.71M | -1.71M | 203.50K |
| EPS Basic | -- | -- | -- | -- | -- |
| Normalized Basic EPS | -- | -- | -- | -- | -- |
| EPS Diluted | -- | -- | -- | -- | -- |
| Normalized Diluted EPS | -- | -- | -- | -- | -- |
| Average Basic Shares Outstanding | -- | -- | -- | -- | -- |
| Average Diluted Shares Outstanding | -- | -- | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |